IP Library Granted Patent US 8,399,384
Granted Patent B2
US 8,399,384 · App. 13/161,441 · Granted Mar 19, 2013

Focused libraries of genetic packages

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,399,384
App. No.
13/161,441
Granted
Mar 19, 2013
Kind
B2
Abstract

Focused libraries of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of antibody peptides, polypeptides or proteins and collectively display, display and express, or comprise at least a portion of the focused diversity of the family. The libraries have length and sequence diversities that mimic that found in native human antibodies.

Claims (62)

1. A focused library of vectors or genetic packages, comprising a first set of variegated DNA molecules, each of which comprises a DNA sequence that encodes an antibody heavy chain (FTC) variable region comprising a CDR1 region, a CDR2 region, and a CDR3 region, wherein the first set of variegated DNA molecules collectively encode a plurality of:

(a) HC CDR1 regions selected from the group consisting of:

(1) <1> 1 Y 2 <1> 3 M 4 <1> 5 (SEQ ID NO:100), wherein <1> is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y;

(2) (S/T) 1 (S/G/X) 2 (S/G/X) 3 Y 4 Y 5 W 6 (S/G/X) 7 (SEQ ID NO:101), wherein (S/T) is a 1:1 mixture of S and T residues, (S/G/X) is a mixture of 0.2025 S, 0.2025, G and 0.035 of each of amino acid residues A, D, E, F, H, I, K, L, M, N, P, Q, R, T, V, W, and Y;

(3) V I S 2 G 3 G 4 S 5 I 6 S 7 <<1> 8 <1> 9 <1> 10 Y 11 Y 12 W 13 <1> 14 (SEQ ID NO:1), wherein <1> is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y; and

(4) a mixture of any of (1) to (3) set forth above;

(b) HC CDR2 regions selected from the group consisting of:

(1) <2>I<2><3>SGG<1>T<1>YADSVKG (SEQ ID NO:2), wherein <1> is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, 5, T, V, W, and Y; <2> is an equimolar mixture of each of amino acid residues Y, R, W, V, G, and S; and <3> is an equimolar mixture of each of amino acid residues P, S, and G or an equimolar mixture of P and S;

(2) <1>I<4><1><1><G><5><1><1>-<1>YADSVKG (SEQ ID NO:3), wherein <1> is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y; <4> is an equimolar mixture of residues D, I, N, S, W, Y; and <5> is an equimolar mixture of residues S, G, D and N;

(3) <1>I<4><1><1>G<5><1><1>YNPSLKG (SEQ ID NO:4), wherein <1> is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and <4> and <5> are as defined above;

(4) <1>I<8>S<1><1><1>GGYY<1>YAASVKG (SEQ ID NO:5), wherein <1> is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; <8> is 0.27 R and 0.027 of each of ADEFGHIKLMNPQSTVWY; and

(5) a mixture of any of (1) to (4) set forth above; or

(c) HC CDR3 regions selected from the group consisting of:

(1) YYCA21111YFDYWG (SEQ ID NO:6), wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R;

(2) YYCA2111111YFDYWG (SEQ ID NO:7), wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R;

(3) YYCA211111111YFDAYTG (SEQ ID NO:8), wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R;

(4) YYCAR111S2S3111YFDYWG (SEQ ID NO:9), wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of S and G; and 3 is an equimolar mixture of Y and W;

(5) YYCA2111CSG11CY1YFDYWG (SEQ ID NO:10), wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R;

(6) YYCA211SITIFG11111YFDYWG (SEQ ID NO:11), wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R;

(7) YYCAR111YY2S3344111YFDYWG (SEQ ID NO:12), wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; 2 is an equimolar mixture of D and S; and 3 is an equimolar mixture of S and G;

(8) YYCAR1111YC2231CY111YFDYWG (SEQ 1D NO:13), wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; 2 is an equimolar mixture of S and G; and 3 is an equimolar mixture of T, D and G; and

(9) a mixture of any of (1) to (8) set forth above.

2. The focused library according to claim 1 , wherein HC CDR1s (1), (2) and (3) are present in the library in the ratio 0.80:0.17:0.02.

3. The focused library according to claim 1 , wherein a mixture of HC CDR2s (1)/(2) (equimolar), (3) and (4) are present in the library in a ratio of 0.54:0.43:0.03.

4. The focused library according to claim 1 , wherein 1 in one or all of HC CDR3s (1) through (8) is 0.095 of each of G and Y and 0.048 of each of A, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, and W.

5. The focused library according to claim 1 , wherein HC CDR3s (1) through (8) are present in the library in the following proportions: (1) 0.10 (2) 0.14 (3) 0.25 (4) 0.13 (5) 0.13 (6) 0.11 (7) 0.04 and (8) 0.10.

6. The focused library according to claim 1 , wherein the HC CDR3s (1) through (8) are present in the library in the following proportions: (1) 0.02 (2) 0.14 (3) 0.25 (4) 0.14 (5) 0.14 (6) 0.12 (7) 0.08 and (8) 0.11.

7. The focused library of vectors or genetic packages according to claim 1 , further comprising a second set of variegated DNA molecules each of which comprises a DNA sequence that encodes an antibody kappa light chain (LC κ ) comprising a LC κ CDR1 region, a LC κ CDR2 region, and a LC κ CDR3 region, wherein the second set of variegated DNA molecules collectively encode a plurality of:

(a) LC κ CDR1 regions selected from the group consisting of:

(1) RASQ<1>V<2><2><3>LA (SEQ ID NO:14),

(2) RASQ<1>V<2><2><2><3>LA (SEQ ID NO:15); wherein <1> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVWY; <2> is 0.2 S and 0.044 of each of ADEFGHIKLMNPQRTVWY; and <3> is 0.2Y and 0.044 each of ADEFGHIKLMNPQRTVW and S; and

(3) a mixture of (1) and (2) set forth above;

(b) LC κ CDR2 regions <1>AS<2>R<4><1> (SEQ ID NO:102), wherein <1> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVWY; <2> is 0.2 S and 0.044 of each of ADEFGHIKLMNPQRTVWY; and <4> is 0.2 A and) 0.044 each of DEFGHIKLMNPQRSTVWY; or

(c) LC κ CDR3 regions selected from the group consisting of:

(1) QQ<3><1><1><1>P<1>T (SEQ ID NO:16), wherein <1> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVWY; <3> is 0.2 Y and 0.044 each of ADEFGHIKLMNPQRTVW;

(2) QQ33111P (SEQ ID NO:103), wherein 1 and 3 are as defined in (1) above;

(3) QQ3211PP1T (SEQ ID NO:17), wherein 1 and 3 are as defined in (1) above and 2 is 0.2 S and 0.044 each of ADEFGHIKLMNPQRTVWY; and

(4) a mixture of any of (1) to (3) set forth above.

8. The focused library of claim 7 , wherein LC κ CDR1s (1) and (2) are present in the library in a ratio of 0.68:0.32.

9. The focused library according to claim 7 , wherein the LC κ CDR3s (1), (2) and (3) are present in the library in a ratio of 0.65:0.1:0.25.

10. The focused library of vectors or genetic packages according to claim 1 , further comprising a third set of variegated DNA molecules each of which comprises a DNA sequence that encodes an antibody lambda light chain (LC λ ) chain comprising a LC λ CDR1 region, a LC λ CDR2 region, and a LC λ CDR3 region, wherein the third set of variegated DNA molecules collectively encodes a plurality of:

(a) LC λ CDR1 regions selected from the group consisting of:

(1) TG<1>SS<2>VG<1><3><2><3>VS (SEQ ID NO:18), wherein <1> is 0.27 T, 0.27 G and 0.027 each of ADEFHIKLMNPQRSVWY, <2> is 0.27 D, 0.27 N and 0.027 each of AEFGHIKLMPQRSTVWY, and <3> is 0.36 Y and 0.036 each of ADEFGHIKLMNPQRSTVW;

(2) G<2><4>L<4><4><4><3><4><4> (SEQ ID NO:104), wherein <2> is as defined in (1) above and <4> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVWY; and

(3) a mixture of (1) and (2) set forth above, or

(b) LC λ CDR2 regions <4><4><4><2>RPS (SEQ ID NO:105), wherein <2> is 0.27 D, 0.27 N, and 0.027 each of AEFGHIKLMPQRSTVWY and <4> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVW, or

(c) LC λ CDR3 regions selected from the group consisting of:

(1) <4><5><4><2><4>S<4><4><4><4>V (SEQ ID NO:106), wherein <2> is 0.27 D, 0.27 N, and 0.027 each of AEFGHIKLMPQRSTVWY; <4> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVW; and <5> is 0.36 S and 0.0355 each of ADEFGHIKLMNPQRTVWY;

(2) <5>SY<1><5>S<5><1><4>V (SEQ ID NO:19), wherein <1> is an equimolar mixture of ADEFGHIKLMNPQRSTVWY; and <4> and <5> are as defined in (1) above; and

(3) a mixture of (1) and (2) set forth above.

11. The focused library according to claim 10 , where LC λ CDR1s (1) and (2) are present in the library in a ratio of 0.67:0.33.

12. The focused library according to claim 10 , wherein LC λ CDR3s (1) and (2) are present in the library in an equimolar mixture.

13. The focused library according to claim 1 , wherein the first set of variegated DNA molecules collectively encode a plurality of HC CDR1s set forth in (a), HC CDR2s set forth in (b), and HC CDR3s set forth in (c).

14. The focused library according to claim 7 , wherein the second set of variegated DNA molecules collectively encode a plurality of LC κ CDR1s set forth in (a), LC κ CDR2s set forth in (b), and LC, CDR3s set forth in (c).

15. The focused library according to claim 10 , wherein the third set of variegated DNA molecules collectively encode a plurality of LC λ CDR1s set forth in (a), LC λ CDR2s set forth in (b), and LC λ CDR3s set forth in (c).

16. The library of vectors or genetic packages according to claim 1 , wherein the library is a library of vectors.

17. The library of vectors or genetic packages according to claim 16 , wherein the vectors are yeast vectors.

18. The library of vectors or genetic packages according to claim 1 , wherein the library is a library of genetic packages.

19. The library of vectors or genetic packages according to claim 18 , wherein the genetic packages are cells, spores, or viral particles.

20. The library of vectors or genetic packages according to claim 19 , wherein the genetic packages are phage particles.

21. The library of vectors or genetic packages according to claim 19 , wherein the genetic packages are yeast cells.

22. The library of vectors or genetic packages according to claim 21 , wherein the yeast cells display the antibody heavy chains encoded by the first set of variegated DNA molecules.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2021
From: DYAX CORP.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 056268/0983 →
RELEASE OF SECURITY INTEREST Recorded Oct 28, 2015
From: LFRP INVESTORS, L.P.
To: DYAX CORP.
Reel/Frame 036902/0703 →
SECURITY AGREEMENT Recorded Aug 22, 2012
From: DYAX CORP., A DELAWARE CORPORATION
To: LFRP INVESTORS, L.P., A DELAWARE LIMITED PARTNERSHIP
Reel/Frame 028828/0517 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2011
From: LADNER, ROBERT C.
To: DYAX CORP.
Reel/Frame 027431/0453 →